Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 6/20 | 0.66 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 3/20 | 0.35 |
| ▸ | HTR3A | P46098 | 2/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12083971 | 0.88 | HPGDS (0.58) | HPGDSGLATRPM8MEN1KMT2A | |
| SCHEMBL14313123 | 0.85 | HPGDS (0.48) | HPGDSGLATRPM8MEN1KMT2A | |
| SCHEMBL12083859 | 0.83 | HPGDS (0.63) | HPGDSGLAMEN1KMT2A | |
| SCHEMBL12084171 | 0.82 | HPGDS (0.44) | HPGDSHTR3A | |
| SCHEMBL12084139 | 0.82 | HPGDS (0.81) | HPGDSGLAMEN1KMT2AKLKB1 | |
| SCHEMBL12084130 | 0.81 | HPGDS (0.61) | HPGDSGLATRPM8MEN1KMT2A | |
| SCHEMBL12083840 | 0.80 | HPGDS (0.65) | HPGDSGLATRPM8MEN1KMT2A | |
| SCHEMBL2474438 | 0.79 | HPGDS (1.00) | HPGDSGLAMEN1KMT2AKLKB1 | |
| SCHEMBL12083846 | 0.79 | HPGDS (0.76) | HPGDSGLAMEN1KMT2AKLKB1 | |
| SCHEMBL12084185 | 0.79 | HPGDS (0.53) | HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2142516-B1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI SA (FR) | 2012-12-26 | — | — | EP | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-8258130-B2 | Pyrimidine hydrazide compounds as PGDS inhibitors | SANOFI (FR) | 2012-09-04 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2010-02-25 | — | — | US | disclosed |
| WO-2008121670-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048568-A1 | PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, HRH4 | HPGDS 10/4885GLA 1529/4885TRPM8 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.